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Abstract page
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Mueller NJ and the Swiss Transplant Cohort Study (STCS)
Clin Transplant
Title: Vitamin D deficiency is common in kidney transplant recipients, but is not associated with 
infections after transplantation
Abstract: The relevance of vitamin D for infections after kidney transplantation is poorly defined. 
25-OH vitamin D (25-OHD) levels of 135 kidney transplant recipients, enrolled in the Swiss 
Transplant Cohort Study, were determined peri-transplant and 6 months post-transplant. Logistic 
regression was used to address associations of 25-OHD and overall infections and bacterial 
infections, respectively. For the first 6 months post-transplant, 25-OHD peri-transplant, and for the 
second period (after 6 to 30 months post-transplant), 25-OHD at 6 months post-transplant was 
considered. Vitamin D deficiency was common peri-transplant and remained highly prevalent 6 
months after transplantation despite frequent supplementation. Median 25-OHD levels increased 
from 12.0ng/ml (IQR 5.3-19.5) peri-transplant to 16.5ng/ml (IQR 10.6-22.6) 6 months post-
transplant (P=0.005). We did not detect a significant association between 25-OHD and overall 
infections (adjusted odds ratio (aOR) 1.05, 95% confidence interval (95%CI) 0.44-2.51; aOR 0.67, 
95%CI 0.31-1.43) or bacterial infections (aOR 0.79, 95%CI 0.32-1.96; aOR 0.79, 95%CI 0.35-
1.75) for the first and second period. To conclude, at both time points vitamin D deficiency was 
observed in more than 50% of kidney recipients, albeit an increase in 25-OHD in the longitudinal 
course was observed. No significant association of 25-OHD and infections was detected.
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Introduction
Vitamin D deficiency has been reported to be frequent among individuals with chronic renal 
failure 1. Ultraviolet light exposure of the skin is considered as the most relevant source of vitamin 
D. Vitamin D itself is biologically not active and requires two hydroxylation steps for activation. 
In the liver an initial hydroxylation occurs resulting in 25-OH vitamin D (25-OHD). 25-OHD 
levels are used to determine vitamin D status. The second hydroxylation takes place in the kidneys 
forming the final active hormone 1, 25-(OH)2 vitamin D 2. Chronic renal failure affects not just the 
exocrine function of the kidneys, but also the endocrine function including activation of 25-OHD. 
In the general population deficiency of vitamin D has been associated with a higher risk of 
infections 3. Among kidney transplant recipients some studies indicate a relevance of 25-OHD 
levels for infections overall 4, bacterial infections 5, urinary tract infections 6 and opportunistic 
viral infections 7. Other studies could not identify an association between vitamin D status and 
infections after kidney transplantation 8. Given the heterogeneity of these reported observations, 
we planned a study within the Swiss Transplant Cohort Study (STCS). In the present study, 
vitamin D levels at time of kidney transplantation and 6 months afterwards were assessed. In 
addition, we specifically addressed the question whether vitamin D status has an association with 
clinically relevant infections. For the most common infectious etiology, i.e. bacterial infections, a 
subgroup analysis was performed. For infections a total follow-up of 2.5 years was divided into 
two periods, the first 6 months post-transplant and after 6 months until 2.5 years post-transplant. 
Our analysis considered the vitamin D status at time of transplantation and at 6 months post-
transplant for the first period and the second period, respectively. 
Patients and Methods
Study design, participants and patient-related data
The present study was a nested project within the Swiss Transplant Cohort Study (STCS, 
www.stcs.ch). For the STCS data and biosamples from every transplant center in Switzerland, i.e. 
Basel, Bern, Geneva, St. Gallen, Lausanne and Zurich, are prospectively collected 9. Approval of 
the STCS was provided by the corresponding Ethics Committees. From all enrolled patients 
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recipients were performed between May 2008 and March 2009. Except information about vitamin 
D supplementation, which was retrospectively added, all remaining data were prospectively 
gathered. Infectious diseases are prospectively recorded by dedicated professionals applying 
definitions established within the STCS and are supervised by transplant infectious diseases 
physicians. For the analyses of an association between vitamin D levels and infectious diseases 
exclusively symptomatic infections and, if possible, prompting targeted treatment, were 
considered. Clinical presentations with suspected infectious etiology resulting in initiation of 
antimicrobial treatment by the treating physicians, were considered as probable infections, if 
routine diagnostics failed to identify a causative pathogen. For the subgroup analysis of bacterial 
infections, we defined proven bacterial infections as clinically apparent infections combined with 
detection of the causative bacterium and initiation of targeted antimicrobial treatment, as 
previously described 10. 
Determination of vitamin D levels
Prospectively, at time of transplant and 6 months afterwards, collected blood samples of the 
participants were retrieved from the STCS biobank and sent to the Institute of Clinical Chemistry 
of the University Hospital Zurich for centralized, uniform measurement. 25-OH vitamin D was 
measured with the Roche Diagnostics Vitamin D total assay on Cobas® 8000 (Roche Diagnostics, 
Mannheim, Germany).
25-OH vitamin D levels < 20ng/ml were categorized as deficiency, whereas 25-OH vitamin D 
levels ≥ 20ng/ml were judged as no deficiency 11.
Statistis
All statistical analyses were performed in R (version 3.3.2). For continuous variables median and 
interquartile ranges (IQR), for categorical variables absolute numbers and frequencies (%) were 
reported. All applied statistical tests were two-sided tests, P-values < 0.05 were considered 
significant. For comparison of continuous variables between two groups Wilcoxon rank-sum test 
was applied, whereas for pairwise comparisons Wilcoxon matched-pairs signed-rank test was 
used. For investigation of the association between vitamin D levels and infections, we defined two 
observation periods. The timespan from transplantation to 6 months post-transplant was referred 
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account. The second period encompassed the timespan after 6 months until 30 months post-
transplant; for this period, 25-OH vitamin D values measured at 6 months after transplantation 
were considered. Patients with shorter follow-up due to death or lost to follow-up were excluded 
from this analysis (1 out of 135 kidney recipients for the second period). For identification of risk 
factors associated with infections logistic regression was performed. In the univariable analysis, 
the variables vitamin D status (no deficiency vs. deficiency), age, sex, type of donation (deceased 
vs. living), induction immunosuppression, body mass index (BMI), and diabetic nephropathy as 
cause of end stage renal disease (ESRD) were tested. For the first period, vitamin D status, age, 
sex and induction immunosuppression, whereas vitamin D status, age and sex for the second 
period were included in the multivariable analyses. Additional variables were added to the 
multivariable model, if P-values reached ≤ 0.10 in univariable analysis
Results
Patients’ characteristics
Participants were predominantly of Caucasian origin (124, 91.9%) with 90 (66.7%) males (Table 
1). Median age was 51 years (IQR 40-62). The most frequent underlying diseases leading to renal 
failure were glomerulonephritis (32, 23.7%), polycystic kidney disease (27, 20.0%), 
nephrosclerosis (17, 12.6%) and diabetic nephropathy (12, 8.9%). One hundred and eight (80.0%) 
participants required renal replacement therapy prior to transplantation, 81 (60.0%) received 
hemodialysis and 27 (20.0%) peritoneal dialysis. In 77 (57.0%) patients living kidney 
transplantation was performed, whereas 58 (43.0%) received a graft from a deceased donor. 
Immunosuppressive therapy included induction therapy in 110 (81.5%) recipients. At time of 
transplantation in 61 (45.2%) participants supplementation therapy with cholecalciferol (median 
dose 800IU/day) and in another 37 (27.4%, in two individuals combined with cholecalciferol) 
participants with 1, 25-dihydroxycholecalciferol (median dose 0.25µg/day) was administered. Six 
months after transplantation 84 (62.2%) kidney recipients received cholecalciferol (median dose 
800IU/day) and 5 (3.7%, in two individuals combined with cholecalciferol) patients 1, 25-
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Vitamin D status
Peri-transplant only a minority of kidney recipients had non deficient levels of 25-OHD (n=31, 
23.0%) (Table 2). The majority of kidney transplant recipients showed deficient levels (n=104, 
77.0%). Six months post-transplant, in 88 (65.2%) kidney transplant recipients vitamin D 
deficiency was present. A significant increase in 25-OHD levels between time of transplantation 
(median 12.0ng/ml, IQR 5.3-19.5ng/ml) and 6 months post-transplant (median 16.5ng/ml, IQR 
10.6-22.6ng/ml) was detectable (P=0.005). Peri-transplant 19.4% of patients receiving 
supplementation treatment with vitamin D analogues had 25-OHD levels of at least 20ng/ml, 
whereas this proportion was 32.4% of patients without supplementation. Six months post-
transplant 25-OHD levels were ≥ 20ng/ml in 46.0% of patients receiving supplementation therapy 
(vs. 10.3% in kidney recipients without supplementation therapy).
Vitamin D status and infections
Infections within the first 6 months post-transplant
In the first 6 months post-transplant a total of 155 infections affecting 75 (55.6%) participants 
were recorded, 78 (50.3%) infections were caused by bacteria, 31 (20.0%) infections by viruses 
and a much lower proportion by fungi (8, 5.2%) and parasites (2, 1.3%) (Table 3). In 36 (23.2%) 
episodes an infectious etiology was suspected and antimicrobial treatment administered, but 
identification of the causative organism failed (i.e. probable infections). The most frequent, by 
bacterial infections affected sites were the urinary tract (n=46, 59.0%), gastrointestinal tract (n=11, 
14.1%), bacteremia (n=13, 12.8%) and respiratory tract (n=3, 3.8%) (Figure 1).
In univariable logistic regression we did not detect an association of infections with vitamin D, 
age, type of donation, induction immunosuppression, BMI and diabetic nephropathy as cause of 
ESRD, respectively (Table 4). Male sex tended to be associated with a lower odds for infections 
(odds ratio (OR) 0.50, 95%CI 0.24 to 1.05; P=0.068). In multivariable analysis male sex was 
significantly protective against infection (adjusted odds ratio (aOR) 0.46, 95%CI 0.22 to 0.99; 
P=0.047), whereas increasing age showed a trend of higher risk (aOR 1.24, 95%CI 0.96 to 1.60; 
P=0.096) (Table 4). 
If we focused exclusively on bacterial infections, aging correlated positively with bacterial 
infections (OR 1.33, 95%CI 1.03 to 1.72; P=0.030) (Table 5). Male sex showed a trend of 
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vitamin D, type of donation, induction immunosuppression and BMI. Diabetic nephropathy as 
etiology of ESRD tended to be associated with a higher risk of bacterial infections (OR 3.13, 
95%CI 0.93 to 10.50; P=0.064). Multivariable logistic regression confirmed increasing age as risk 
factor (aOR 1.39, 95%CI 1.03 to 1.87; P=0.031) and the protective effect of male sex (aOR 0.42, 
95%CI 0.19 to 0.92; P=0.033).
Infections after 6 up to 30 months post-transplant
After 6 until 30 months post-transplant, totally 168 infections occurring in 70 (51.9%) of 
participants were observed. 78 (46.4%) infections were caused by bacteria, 34 (20.2%) by viruses, 
3 (1.8%) by fungi and 4 (2.4%) by parasites (Table 3). In 49 (29.2%) episodes identification of a 
causative pathogen failed, but an antimicrobial therapy initiated. Bacterial infections most 
frequently were urinary tract infections (n = 53, 68.0%), gastrointestinal infections (n = 6, 7.7%), 
respiratory tract infections (n = 6, 7.7%) or bacteremia (n = 4, 5.1%) (Figure 1).
Univariable logistic regression showed a trend of a reduced odds of infection for male sex (OR 
0.49, 95%CI 0.23 to 1.03; P=0.058), which was also present in multivariable analysis (aOR 0.50, 
95%CI 0.23 to 1.07; P=0.074), whereas no association was detected for other variables (Table 4).
Analysis of bacterial infections solely indicated a protective effect of male sex for infections 
(univariable OR 0.42, 95%CI 0.20 to 0.89; P=0.025; multivariable aOR 0.41, 95%CI 0.19 to 0.88; 
P = 0.022). We did not detect an association between vitamin D levels and bacterial infections in 
the second period after kidney transplantation (Table 5). 
Discussion
In the present study vitamin D levels of kidney allograft recipients were determined by uniform 
measurement using prospectively collected samples at the time of transplantation and 6 months 
thereafter. Vitamin D deficiency was highly prevalent at time of transplantation, and 6 months 
after transplantation still more than half of transplant recipients did not have sufficient 25-OHD 
levels. Our analyses did not detect a significant association between vitamin D status and 
clinically relevant infections and bacterial infections for both observation periods, respectively.
The finding of common vitamin D deficiency is likely due to multiple factors. Supplementation 
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of vitamin D to gain sufficient 25-OHD levels. Post-transplant alterations of specific pathways 
influencing vitamin D metabolism may be relevant. Such, higher levels of fibroblast growth factor 
23 (FGF-23) have been demonstrated following kidney transplantation 12. FGF-23 inhibits 1-
position hydroxylation of 25-OHD and promotes degradation of 1, 25-(OH)2 vitamin D 13, which 
could contribute to an increased requirement of supplementation. Further, transplant recipients 
avoid sun exposure with respect to the increased risk of skin cancer in the context of 
immunosuppressive treatment. 
In literature, hypotheses for the relevance of vitamin D in infections have been generated. 
Monocytes and macrophages can produce the active form of vitamin D, i.e. 1, 25-(OH)2 vitamin 
D, via CYP27B1-hydroxylase requiring circulating 25-OHD as substrate. Vitamin D receptor-
directed genes, e.g. cathelicidin, are activated by 1, 25-(OH)2 vitamin D triggering killing of 
ingested pathogens 14,15. LL-37, which is the active form of cathelicidin, has the capability to break 
bacterial membranes and viral envelopes 16. Beyond, increasing evidence indicates presence of this 
pathway in barriers like skin 17, gut 18 and lung 19. Insufficient 25-OHD levels might impede this 
pathway. In our multicenter study with prospectively collected data and uniform 25-OHD 
measurement, we were not able to detect a correlation of vitamin D status with clinically relevant 
infections or bacterial infections. Notably, also in an additional analysis on opportunistic 
infections we could not detect an association with vitamin D status (Supplemental Table). These 
findings are in line with the results of Ban Th et al 8,20. Few studies, most of them based on 
retrospective data collection, reported an association between vitamin D deficiency and infections 
4,6,21. The cut-off value used for definition of vitamin D deficiency in our study is based on studies 
that considered dynamics in bone turnover variables 11. Up to now, no cut-off has been specifically 
established for infectious risk stratification by vitamin D status. Notably, in an analysis 
considering vitamin D levels as continuous variable, we also did not detect an association with 
infections (data not shown). It can be speculated that there might be a publication bias in this 
context with a relevant number of negative studies unpublished. In the first observation period 
male sex was associated with a protective effect from both, clinically relevant infections and 
bacterial infections. In the second observation period this effect was only observed for bacterial 
infections. This observation might be also due to the high frequency of urinary tract infections and 
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Limitations of our study are the limited number of participants and the retrospective collection of 
information on vitamin D supplementation. Furthermore, we did not collect information on the 
need of hospitalization due to an infection thus hindering an analysis addressing the question of a 
difference in severity of infectious disease events by vitamin D status. Strengths include serial, 
uniform measurements of 25-OHD, the cohort study design with follow-up data up to 2.5 years 
post-transplant for the vast majority of patients (99.3%).
To conclude, our study showed a relevant proportion of participants remaining vitamin D deficient 
despite a high frequency of supplementation. Our findings do not support a relevant role of 
vitamin D in infections after kidney transplantation.  
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Tables:
Table 1: Baseline characteristics
Variable
Age (median (IQR)) 51y (40, 62)
Sex (n, %) Male 90 (66.7%)
Female 45 (33.3%)
Ethnicity (n, %) Caucasian 124 (91.9%)
African 5 (3.7%)
Asian 5 (3.7%)
American Indian 1 (0.7%)
Underlying disease (n, %) Glomerulonephritis 32 (23.7%)
Polycystic kidney disease 27 (20.0%)
Nephrosclerosis 17 (12.6%)
Diabetic nephropathy 12 (8.9%)
Reflux nephropathy 9 (6.7%)
Cause unknown 12 (8.9%)
Other 26 (19.3%)
Renal replacement therapy (n, %) HD: 81 (60.0%)
PD: 27 (20.0%)
None: 27 (20.0%)
Type of donation (n, %) DBD 58 (43.0%)
living related 39 (28.9%)
living unrelated 38 (28.1%)
Induction therapy (n, %) Basiliximab 89 (65.9%) (7 combined with Anti-T-lymphocyte-
immunoglobulin)
Anti-T-lymphocyte-immunoglobulin 10 (7.4%) (4 combined with 
IVIG)
Rituximab 4 (3.0%)
Other regimen 7 (5.2%)
None 25 (18.5%)
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Supplementation of vitamin D (n, %) peri-transplant)
cholecalciferol 61 (45.2%)
1, 25-dihydroxycholecalciferol 37** (27.4%)
6 months post-transplant
cholecalciferol 84 (62.2%)
1, 25-dihydroxycholecalciferol 5*** (3.7%)
* 6 months after transplantation
** in 2 participants supplementation with cholecalciferol and 1, 25-dihydroxycholecalciferol
*** in 2 participants supplementation with cholecalciferol and 1, 25-dihydroxycholecalciferol
Abbreviations: CsA: cyclosporine A, DBD: donation after brain death, EC-MPA: enteric-coated mycophenolate, HD: 
hemodialysis, IVIG: intravenous immunoglobulins, MMF: mycophenolate mofetil, PD: peritoneal dialysis, RRT: 
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Table 2: Vitamin D status peri-transplant and 6 months after transplantation
Vitamin D status Peri-transplant 6 months post-transplant*
Deficiency 104 (77.0%) 88 (65.2%)
No deficiency 31 (23.0%) 46 (34.1%)
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Table 3: Infections in the first 6 months after transplantation and 6 to 30 months after 
transplantation
Period Pathogen Site of infection Bacterial/viral/fungal/parasitic species








Coagulase negative staphylococci (n=11)
Clostridium spp. (n=5)
Other gram-positive bacteria (n=4)
Other gram-negative bacteria (n=2)
Other bacteria (n=6)







Human herpes virus 1/2 (n=8)
Cytomegalovirus (n=3)
Varicella zoster virus (n=2)
Respiratory viruses (n=5)
Other viruses (n=4)







Parasitic infection (n=2) Gastrointestinal tract (n=2) Not specified (n=2)
First 6 m
onths post-transplant

















Other Enterobacteriaceae (n=6) 
Other gram-positive bacteria (n=5)
Other gram-negative bacteria (n=4)
Other bacteria (n=13)
6 to 30 m

















Human herpes virus 1/2 (n=5)
Varicella zoster virus (n=4)
Respiratory viruses (n=4)
Gastrointestinal viruses (n=9)






Parasitic infection (n=4) Skin (n=3)
Other site (n=1)
Not specified (n=4)







* 15 infections with detection of two bacterial species
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Table 4: Logistic regression analysis of risk for infections within the first 6 months post-transplant and after 6 up to 30 months post-
transplant
first 6 months post-transplant after 6 up to 30 months post-transplant
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Odds ratio (95%CI) P Odds ratio (95%CI) P Odds ratio (95%CI) P Odds ratio (95%CI) P
Vitamin D status
   No deficiency
   Deficiency
Reference
0.88 (0.39 to 1.97) 0.749
Reference
1.05 (0.44 to 2.51) 0.916
Reference
0.75 (0.37 to 1.54) 0.157
Reference
0.67 (0.31 to 1.43) 0.299
Age
   Per decade increase 1.19 (0.95 to 1.48) 0.128 1.24 (0.96 to 1.60) 0.096 0.89 (0.71 to 1.10) 0.278 0.85 (0.67 to 1.07) 0.168
Sex
   Female
   Male
Reference
0.50 (0.24 to 1.05) 0.068
Reference
0.46 (0.22 to 0.99) 0.047
Reference
0.49 (0.23 to 1.03) 0.058
Reference
0.50 (0.23 to 1.07) 0.074
Type of donation
   Living
   Deceased
Reference
1.41 (0.71 to 2.81) 0.332
Reference
0.99 (0.50 to 1.98) 0.985
Induction immunosuppression
   None
   Any
Reference
1.19 (0.50 to 2.85) 0.692
Reference
0.85 (0.32 to 2.25) 0.743
Reference
0.99 (0.42 to 2.37) 0.989
BMI*
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   Any other etiology
   Diabetic nephropathy
Reference
2.59 (0.67 to 10.03) 0.168
Reference
3.10 (0.80 to 12.01) 0.101
Reference
3.15 (0.78 to 12.70) 0.106
* BMI (body mass index) determined at time of transplantation and at 6 months post-transplant used for analysis of incident infections within first 6 months post-transplant and 
after 6 up to 30 months post-transplant, respectively
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Table 5: Logistic regression analysis of risk for bacterial infections within the first 6 months post-transplant and after 6 up to 30 months 
post-transplant
first 6 months post-transplant after 6 up to 30 months post-transplant
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Odds ratio (95%CI) P Odds ratio (95%CI) P Odds ratio (95%CI) P Odds ratio (95%CI) P
Vitamin D status
   No deficiency
   Deficiency
Reference
0.62 (0.27 to 1.41) 0.249
Reference
0.79 (0.32 to 1.96) 0.608
Reference
0.84 (0.40 to 1.80) 0.660
Reference
0.79 (0.35 to 1.75) 0.557
Age 
   Per decade increase 1.33 (1.03 to 1.72) 0.030 1.39 (1.03 to 1.87) 0.033 1.01 (0.80 to 1.27) 0.966 1.01 (0.79 to 1.29) 0.929
Sex
   Female
   Male
Reference
0.48 (0.23 to 1.02) 0.055
Reference
0.42 (0.19 to 0.92) 0.031
Reference
0.42 (0.20 to 0.89) 0.025
Reference
0.41 (0.19 to 0.88) 0.022
Type of donation
   Living
   Deceased
Reference
1.25 (0.61 to 2.58) 0.539
Reference
0.99 (0.47 to 2.06) 0.969
Induction immunosuppression
   None
   Any
Reference
1.08 (0.43 to 2.73) 0.876
Reference
0.62 (0.21 to 1.81) 0.383
Reference
2.17 (0.76 to 6.25) 0.150
BMI*
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   Any other etiology
   Diabetic nephropathy
Reference
3.13 (0.93 to 10.50) 0.064
Reference
2.44 (0.70 to 8.53) 0.163
Reference
2.27 (0.69 to 7.51) 0.179
* BMI (body mass index) determined at time of transplantation and at 6 months post-transplant used for analysis of incident infections within first 6 months post-transplant and 
after 6 up to 30 months post-transplant, respectively
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Figure Legends:
Figure 1: Site of infection in proven bacterial infections in the first period (first 6 months after 
transplantation) and second period (after 6 up to 30 months after transplantation), respectively
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